Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
Conditions
Interventions
CLN-978
Locations
6
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
City of Hope
Duarte, California, United States
Winship Cancer Institute at Emory University
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Start Date
May 31, 2023
Primary Completion Date
November 1, 2026
Completion Date
April 1, 2027
Last Updated
May 2, 2024
NCT05442515
NCT06230224
NCT06528301
NCT05098613
NCT07283796
NCT06731699
Lead Sponsor
Cullinan Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions